Shattuck Labs, Inc.
STTK
$-0.09
Change (1 day)
$11.76
Year High
$1.02
Year Low
Categories
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.
Earnings for Shattuck Labs, Inc. (STTK)
Earnings in 2023 (TTM): $-87,298,000
According to Shattuck Labs, Inc.'s latest financial reports the company's current earnings (TTM) are $-87,298,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Shattuck Labs, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-87,298,000 | $-87,298,000 |
| 2022 | $-101,945,000 | $-100,561,000 |
| 2021 | $-44,974,000 | $-44,349,000 |
| 2020 | $-36,603,000 | $-35,436,000 |
| 2019 | $-23,982,000 | $-23,883,000 |
| 2018 | $-7,388,000 | $-7,388,000 |